Cargando…
In Vivo RNA Delivery to Hematopoietic Stem and Progenitor Cells via Targeted Lipid Nanoparticles
[Image: see text] Ex vivo autologous hematopoietic stem cell (HSC) gene therapy has provided new therapies for the treatment of hematological disorders. However, these therapies have several limitations owing to the manufacturing complexities and toxicity resulting from required conditioning regimen...
Autores principales: | Shi, Dennis, Toyonaga, Sho, Anderson, Daniel G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103292/ https://www.ncbi.nlm.nih.gov/pubmed/36988645 http://dx.doi.org/10.1021/acs.nanolett.3c00304 |
Ejemplares similares
-
Megakaryocyte membrane‐wrapped nanoparticles for targeted cargo delivery to hematopoietic stem and progenitor cells
por: Das, Samik, et al.
Publicado: (2022) -
Nanoparticles targeting hematopoietic stem and progenitor cells: Multimodal carriers for the treatment of hematological diseases
por: Cruz, Luis J., et al.
Publicado: (2022) -
Degradable Lipid Nanoparticles with Predictable In Vivo
siRNA Delivery Activity
por: Whitehead, Kathryn A., et al.
Publicado: (2014) -
Engineering human megakaryocytic microparticles for targeted delivery of nucleic acids to hematopoietic stem and progenitor cells
por: Kao, Chen-Yuan, et al.
Publicado: (2018) -
Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing
por: Zhang, Xinfu, et al.
Publicado: (2020)